Stock Markets April 15, 2026 04:35 PM

QuidelOrtho Shares Drop After Company Lowers Preliminary Q1 2026 Revenue Outlook

Preliminary guidance misses Street estimates as softer respiratory season and international headwinds weigh on diagnostics sales

By Caleb Monroe QDEL
QuidelOrtho Shares Drop After Company Lowers Preliminary Q1 2026 Revenue Outlook
QDEL

QuidelOrtho Corporation's stock tumbled sharply in after-hours trading after the diagnostics firm issued preliminary revenue guidance for the first quarter of 2026 well below analyst expectations. Management cited a notably weaker respiratory season in the U.S., slower distributor activity in China tied to proposed reimbursement changes, and delayed orders in parts of EMEA as key drivers of the shortfall. The company also provided a negative free cash flow outlook for the quarter and reiterated plans to publish full results on May 5, 2026.

Key Points

  • QuidelOrtho issued preliminary Q1 2026 revenue guidance of $615 million to $620 million, below the Wall Street consensus of $679.59 million.
  • The company cited a roughly 30% decline in U.S. Influenza-like Illness visits versus Q1 2025, slower distributor sales in China linked to proposed reimbursement rate reductions, and order delays in EMEA due to the Middle East conflict - factors that pressured revenue.
  • QuidelOrtho expects negative free cash flow of $65 million to $70 million for Q1 2026 and is pursuing cost reduction measures to support full-year 2026 performance.

QuidelOrtho Corporation (NASDAQ:QDEL) saw its shares fall about 21% in extended trading Wednesday after the company issued preliminary revenue guidance for the first quarter of 2026 that fell short of Wall Street's consensus.

Management said it now expects revenue for the quarter to be in the range of $615 million to $620 million. That guidance compares with the consensus estimate of $679.59 million and represents a substantial downside to market expectations.

The company attributed the revenue gap in part to a softer-than-expected respiratory season in the United States. Management reported that U.S. Influenza-like Illness visits were down approximately 30% versus the first quarter of 2025, a decline it identified as materially affecting demand dynamics.

QuidelOrtho also pointed to weaker distributor shipments in China, which the company believes are related to proposed reductions in reimbursement rates by the China National Health Security Administration. In addition, the firm said certain orders across Europe, the Middle East, and Africa were delayed amid the conflict in the Middle East.

On cash flow, the diagnostics company expects free cash flow to be in the range of negative $65 million to negative $70 million for Q1 2026. That outlook aligns with prior commentary from the company during its fourth quarter 2025 conference call in February, when management indicated it expected negative free cash flow through the first half of 2026 while maintaining an expectation of positive free cash flow for the full year of 2026.

Chief Executive Officer Brian J. Blaser said the company’s core business - which represents more than 70% of total revenue - remains strong despite the softer respiratory season and broader macroeconomic headwinds. The company is implementing cost reduction measures that it says are intended to improve performance for full-year 2026.

QuidelOrtho plans to publish complete first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. Management emphasized that the preliminary revenue figures are based on its initial analysis and remain subject to adjustment as the company completes its quarter-end financial close process.


This report aims to present the company's preliminary guidance and the factors management identified as influencing results. Investors will receive a full accounting of the quarter when the company files its complete financials on the scheduled release date.

Risks

  • A softer respiratory season reducing demand for diagnostics could continue to weigh on company revenues and affect the broader diagnostics and healthcare sector.
  • Proposed reimbursement rate reductions in China represent a policy risk that may slow distributor sales and impact international revenue streams for medical device and diagnostics companies.
  • Operational disruptions and order delays tied to geopolitical conflict in the Middle East could further postpone revenue recognition and strain supply chains in affected regions.

More from Stock Markets

Spirit Aviation's Bankruptcy Outcome Uncertain as Fuel Prices Rise Apr 15, 2026 General Dynamics Secures $44.4M Modification for Stryker Diagnostics; Electric Boat Added to $37.6M Submarine Support Change Apr 15, 2026 Raytheon Secures $234.7M Award to Move AMRAAM ER Into Production Apr 15, 2026 Lockheed Martin Wins $868 Million in U.S. Defense Awards for Trident and F-35 Programs Apr 15, 2026 Mexican Equities Close Higher; S&P/BMV IPC Advances 1.01% Apr 15, 2026